Cody Hastings

Upstream Process Development Scientist at LOTTE BIOLOGICS

Role: Upstream Process Development Scientist at LOTTE Biologics
Location: Binghamton, NY, US
LinkedIn followers: 500 followers

ScienceView LinkedIn profile

About Cody Hastings

Upstream Process Development Scientist specializing in early-stage CHO fed-batch…

Experience

Upstream Process Development Scientist
LOTTE Biologics
Jul 2023 — Present · Syracuse, NY, US
Acted as Subject Matter Expert for AMBR250 System, developed scale down model for processes at the AMBR scaleDelivered several pilot scale toxicology cell culture lots for clients

Education

Rochester Institute of Technology
Bachelor’s Degree
2012 — 2015
Binghamton University
Doctor of Philosophy - PhD
2017 — 2023

Contact information

Verified work emails, personal emails, and direct dials — unlocked in one click.

Work email
•••••@lottebiologics.com
Personal email
•••••@•••••.com
Direct dial
+•• ••• ••• ••••

Unlock verified contacts

Free to start · No credit card required

Current company

LOTTE Biologics

Pharmaceutical Manufacturing · 615 employees · Seoul, South Korea

Founded in 2022 and headquartered in Seoul, South Korea, LOTTE Biologics operates integrated biologics facilities in the United States and South Korea. Through a unified Dual Hub Service model, LOTTE Biologics enhances supply security, supports manufacturing scalability, and maintains consistent quality standards across regions. LOTTE Biologics provides modular, phase-appropriate manufacturing solutions spanning preclinical through commercial stages, with proven capability in producing mammalian-cell-based biologics, including monoclonal antibodies, fusion proteins, and multispecific modalities. At the Syracuse Bio Campus in New York, LOTTE Biologics delivers high-quality GMP drug substance manufacturing supported by more than 62 global regulatory approvals. The site offers 40,000 L of total capacity across eight 5,000 L stainless steel bioreactors and includes analytical and warehouse infrastructure. In addition, the company has expanded into Antibody-Drug Conjugates (ADCs) through strategic investment in onsite conjugation suites, enabling a streamlined, end-to-end pathway from biologic drug substance production to ADC manufacturing within a single campus. In South Korea, LOTTE Biologics is constructing three advanced bio plants at the Songdo Bio Campus. With the first facility already underway and scheduled for operation in 2027, each plant will include eight 15,000 L stainless steel bioreactors for commercial production, supported by multiple 3,000 L bioreactors for clinical-scale needs. Collectively, these plants will provide a manufacturing volume exceeding 360,000L in bioreactor capacity. Guided by the vision “Possibilities Beyond Limits,” LOTTE Biologics is committed to serving as a long-term, trusted partner, supporting efficient scale-up, dependable manufacturing execution, and the continuous advancement of clients’ therapeutic programs.

lottebiologics.com

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Start for free See how it works

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

About Cody Hastings

Experience

Upstream Process Development Scientist

Education

Rochester Institute of Technology

Binghamton University

Find verified contacts for anyone on LinkedIn